Niktimvo margin contribution is expected to be 20% to 30% of net sales in the near term, improving as sales grow.
Niktimvo net revenue was $36.2 million in Q2 2025, with Syndax's 50% share of product contribution amounting to $9.4 million, making it profitable in its first full quarter.
Operating expenses are expected to remain stable over the next few years while fully funding strategic priorities.
Operating expenses increased due to commercialization and ongoing trials, with R&D at $62.2 million and SG&A at $43.8 million in Q2 2025.
Revuforj net revenue increased 43% quarter-over-quarter to $28.6 million in Q2 2025.
Syndax maintains a strong balance sheet with $518 million in cash, equivalents, and investments as of June 30, 2025.
Syndax reported combined net product sales of nearly $100 million for Revuforj and Niktimvo in the first half of 2025, significantly exceeding expectations.
Cash balance ended at $61.7 million, down from $67.9 million in Q1, mainly due to inventory purchases ahead of tariffs.
Evolus reported Q2 2025 global net revenue of $69.4 million, a 4% increase over Q2 2024, driven by the successful launch of Evolysse and international growth.
GAAP operating expenses decreased to $55.5 million from $61.8 million in Q1, while non-GAAP operating expenses increased slightly to $54 million from $52.9 million.
Non-GAAP operating loss was $7.9 million compared to non-GAAP operating income of $1.1 million in Q2 2024.
Reported gross margin was 65.3%, adjusted gross margin was 66.5%, impacted by higher international sales mix and introductory pricing for Evolysse.
Toxin revenue was $59.7 million and HA gels revenue was $9.7 million in Q2 2025.
Dafinchi